1. Volume 11, Issue 1, Pages 66-74 (January 2010)
Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial 
Prof Jeffrey S Tobias, FRCP, Kathryn Monson, MSc, Nirmal Gupta, FRCR, Prof Hugh MacDougall, FRCR, Prof John Glaholm, FRCR, Prof Iain Hutchison, FRCS, Latha Kadalayil, PhD, Allan Hackshaw, MSc 
The Lancet Oncology 
Volume 11, Issue 1, Pages (January 2010)
DOI: /S (09)
Copyright © 2010 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
EFS=event-free survival. SIM=radiotherapy with two courses of chemotherapy given simultaneously on days 1 and 14 of radiotherapy. SUB= radiotherapy with two courses of chemotherapy given 14 and 28 days after completing radiotherapy. *See table 2. Only 26 patients did not fully meet the eligibility criteria, but they were included in the analysis.
The Lancet Oncology  , 66-74DOI: ( /S (09) )
Copyright © 2010 Elsevier Ltd Terms and Conditions

3. Figure 2
Overall survival according to treatment groups for patients who had no surgery (A) and those who had undergone surgery (B) before randomisation
SIM=radiotherapy with two courses of chemotherapy given simultaneously on days 1 and 14 of radiotherapy. SUB= radiotherapy with two courses of chemotherapy given 14 and 28 days after completing radiotherapy.
The Lancet Oncology  , 66-74DOI: ( /S (09) )
Copyright © 2010 Elsevier Ltd Terms and Conditions

4. Figure 3
Event-free survival (EFS) according to treatment groups for patients who had no surgery (A) and those who had undergone surgery (B) before randomisation
SIM=radiotherapy with two courses of chemotherapy given simultaneously on days 1 and 14 of radiotherapy. SUB= radiotherapy with two courses of chemotherapy given 14 and 28 days after completing radiotherapy.
The Lancet Oncology  , 66-74DOI: ( /S (09) )
Copyright © 2010 Elsevier Ltd Terms and Conditions